Sarepta Therapeutics (SRPT) Down 17.7% Since Last Earnings Report: Can It Rebound?Zacks Investment Research • 03/29/19
How This Biotech Stock Is Reinforcing Its Ironclad Hold On A Key MarketInvestors Business Daily • 03/28/19
Sarepta Therapeutics stock up 3.4% after Phase 3 interim analysis shows positive results for DMD drugMarket Watch • 03/28/19
Sarepta Looks To Remain The Leader In DMD Treatment With Latest Gene Therapy DataSeeking Alpha • 03/28/19